SOHO 2022 Tenth Annual Meeting

 

SOHO 2022 Tenth Annual Meeting
Avatar

Phase 1/2 BRUIN Study - Updated Results on Pirtobrutinib in Previously Treated MCL

By SOHO 2022 Tenth Annual Meeting FEATURING Jonathon Cohen
By SOHO 2022 Tenth Annual Meeting FEATURING Jonathon Cohen
108 views
October 14, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
Lymphoma
10:00
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Biology and Treatment of LGL Leukemia

Feat. T. Loughran
10:35
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: Hodgkin Lymphoma

Feat. N. Bartlett
10:19
SOHO 2022 Tenth Annual Meeting

Next Questions: Mantle Cell Lymphoma

Feat. K. Maddocks
11:27
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: T-Cell Lymphoma

Feat. S. Iyer
12:37
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: Follicular Lymphoma

Feat. G. Salles
15:31
SOHO 2022 Tenth Annual Meeting

SOHO 2022: What's Next in Aggressive B-Cell Lymphoma?

Feat. L. Sehn
10:34
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: Cellular Therapy

Feat. K. Komanduri
16:19
SOHO 2022 Tenth Annual Meeting

SOHO 2022 DEBATE: CAR T-Cell vs. AUTO HCT for R/R DLBCL - Pro AUTO H…

Feat. C. Sauter
12:05
SOHO 2022 Tenth Annual Meeting

SOHO 2022 DEBATE: CAR T-Cell vs. AUTO HCT for R/R DLBCL - Pro CAR T-…

Feat. M. Kamdar
08:34
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Camidanlumab Tesirine - Updated Efficacy and Safety in Pa…

Feat. A. Herrera
16:42
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Treating Hodgkin Lymphoma After Brentuximab Vedotin and A…

Feat. A. Herrera
16:18
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Sequencing Novel Agents in Frontline and Second-Line Trea…

Feat. A. Moskowitz
07:04
SOHO 2022 Tenth Annual Meeting

Phase 1/2 BRUIN Study - Updated Results on Pirtobrutinib in Previous…

Feat. J. Cohen
19:47
SOHO 2022 Tenth Annual Meeting

Emerging Treatment Options for MCL

Feat. J. Ruan
13:18
SOHO 2022 Tenth Annual Meeting

Immunotherapeutic Options for Patients With MCL Who Progress on BTK …

Feat. J. Cohen
14:31
Tycel Phillips

The Role of Targeted Therapies in Frontline Treatment of MCL

16:52
SOHO 2022 Tenth Annual Meeting

Is it Time to Recognize the Biological Heterogeneity of MCL?

Feat. A. Goy
08:47
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Cost-Effectiveness of Polatuzumab Vedotin in Previously U…

Feat. J. Burke
08:56
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Results from POLARIX, a Phase III Study of Pola-R-CHP vs.…

Feat. C. Flowers
13:55
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Managing the Elderly Patient With Aggressive B-cell Lymph…

Feat. C. Thieblemont
11:32
SOHO 2022 Tenth Annual Meeting

SOHO 2022: CNS Prophylaxis in DLBCL

Feat. V. Orellana-Noia
14:57
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Treatment of Aggressive B-cell Lymphoma Post-CAR T-Cell T…

Feat. G. Nowakowski
15:19
SOHO 2022 Tenth Annual Meeting

SOHO 2022: The Emerging Potential of Bispecific Antibodies as Monoth…

Feat. M. Dickinson
15:03
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Choosing CAR T-Cell Therapy vs. ASCT in R/R Aggressive B-…

Feat. M. Kamdar
15:33
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Has R-CHOP Really Been Replaced as Initial Therapy of DLB…

Feat. J. Friedberg
05:56
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Pivotal Results From a Phase I/II Study of Mosunetuzumab …

Feat. L. Nastoupil
19:37
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Using Biology to Determine Type and Duration of Treatment…

Feat. P. Kapoor
15:04
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Future Role of Bispecific Antibodies in the Treatment of …

Feat. E. Budde
15:37
SOHO 2022 Tenth Annual Meeting

SOHO 2022: What Is the Role of Transplantation for FL in the Era of …

Feat. M. Hamadani
15:08
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Sequencing Therapy in Indolent Lymphoma - Treatment Choic…

Feat. L. Nastoupil
10:04
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Correlation of TRBC1 by Flow Cytometry With Molecular T-C…

Feat. T. Dexter
14:13
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Advances in the Treatment of NK/T Cell Lymphoma

Feat. W. Kim
16:35
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Integrating Novel Agents Into the Management of Cutaneous…

Feat. P. Allen
15:40
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Novel Treatment Approaches in Relapsed/Refractory PTCL

Feat. M. Lunning
15:49
SOHO 2022 Tenth Annual Meeting

SOHO 2022: The Next Rational Therapeutic Regimen in Newly Diagnosed …

Feat. N. Mehta-Shah
14:21
SOHO 2022 Tenth Annual Meeting

SOHO 2022: From Bench to Bedside - A Translational Scientist's …

Feat. F. Vega
21:46
SOHO 2022 Tenth Annual Meeting

SOHO 2022: CAR T-Cells in Indolent B-Cell Lymphomas

Feat. J. Abramson
18:24
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Challenging Cases in Rare T-Cell Lymphomas

Feat. S. Barta
11:16
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Basis for Targeting the Microenvironment in Hodgkin Lymph…

Feat. C. Steidl
11:27
SOHO 2022 Tenth Annual Meeting

SOHO 2022: CAR T-Cell Therapy in Hodgkin Lymphoma

Feat. C. Ramos
13:22
SOHO 2022 Tenth Annual Meeting

SOHO 2022: The Next Generation of Novel Agents in Development for Ag…

Feat. J. Westin